MedWatch

Oncology Venture has USD 8.7 million deficit after nine months

Biotech company Oncology Venture has significantly increased its deficit in the third quarter, and for the first three quarters as a whole, but the company's finances are comfortable going into 2020, says the new finance director.

Henrik Moltke, finance director at Oncology Venture Photo: PR / Oncology Venture

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try MedWatch for 14 days.

Get a trial subscription here.

Do you want a trial subscription with multiple users for yourself and your colleagues?

Read more about your options and find the contact information to our sales team here.

Related articles